SLC5A2 and diabetes mellitus: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors, initially indicated specifically for the management of type-2 diabetes, have demonstrated a marked beneficial effect in terms of cardiovascular complications in the setting of diabetes [32,33].